Latin America Lung Cancer Therapeutics Market Report

Latin America Lung Cancer Therapeutics Market Size

The Latin America lung cancer therapeutics market size was valued at USD 1.12 billion in 2025 and is anticipated to reach USD 1.20 billion in 2026 from USD 2.11 billion by 2034, growing at a CAGR of 7.29% during the forecast period from 2026 to 2034.

Lung Cancer is an uninhibited expansion of abnormal cells that initiates off in one or both lungs; for the maximum part in the cells that line the air units. The immediate cells don’t form into solid lung tissue but they expand rapidly and form tumors. As cancer becomes bigger and more in number, they decline the lung’s ability to deliver the bloodstream with oxygen.

Air pollution, amplified alcohol consumption, varying lifestyle, smoking, unhealthy food, and no physical activity are the factors indirectly driving the market. Governments in developing economies like the Latin America region are providing awareness among the people about cancer.

The high cost of the treatment and lack of consciousness among the people for initial recognition of cancer are detained for lung cancer therapeutics market.

Regionally, Mexico is dominating the Latin America region's lung cancer therapeutics market and estimated to continue its dominance over the forecast period, while Argentina is expected to witness high growth in the coming years.

REPORT COVERAGE

KEY MARKET PLAYERS

Prominent companies leading in the Latin American Lung Cancer Therapeutics Market include

• Boehringer Ingelheim GmbH
• F. Hoffmann-La Roche
• Pfizer Inc.
• GlaxoSmithKline
• Eli Lilly and Company
• Agennix AG
• AstraZeneca plc
• Sanofi-Aventis

MARKET SEGMENTATION

This research report on the Latin America Lung Cancer Therapeutics Market is segmented and sub-segmented into the following categories.

By Treatment Type

• Chemotherapy
  • Cisplatin
  • Taxol
  • Navelbine
  • Camptosar
  • Alimta
• Radiotherapy
  • External Beam
  • Internal Beam
  • Systemic
• Other Drugs
  • Abraxane
  • Avastin
  • Crizotinib
  • Docetaxel
  • Gefitinib

By Country

• Mexico
• Brazil
• Argentina
• Chile
• Rest of Latin America